Ascendis Pharma (ASND) received an analyst rating upgrade from Morgan Stanley's Vikram Purohit, shifting from an "Equal-Weight" to an "Overweight" status. This upgrade reflects a positive outlook on the company's future performance.
In addition to the rating change, Morgan Stanley has significantly raised the price target for Ascendis Pharma (ASND, Financial) from $180.00 to $250.00. This adjustment represents a substantial 38.89% increase in the price target. The revision underscores growing confidence in the firm's growth prospects.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.